• In June 2026, NeoGenomics, Inc. announced it had appointed Carolyn Starrett, former Flatiron Health CEO and experienced healthcare data and AI leader, to its Board of Directors.
• Her background in applying AI and real-world data to cancer care and drug development could meaningfully influence how NeoGenomics develops and commercializes its oncology testing and digital solutions.
• We’ll now examine how Starrett’s AI and data-driven oncology expertise may influence NeoGenomics’ existing investment narrative and long-term business direction.

Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

NeoGenomics Investment Narrative Recap

To own NeoGenomics, you need to believe its expanding oncology test menu and digital tools can eventually support a path toward more predictable growth and narrower losses. The Starrett appointment does not change the near term focus on ramping PanTracer and managing pharma services volatility, but it may modestly strengthen the company’s ability to use AI and real world data at scale. The biggest immediate risk remains uneven pharma and biotech demand, which still drives revenue volatility.

Among recent announcements, the Epic Aura integration in April 2026 looks most relevant here, because it directly ties NeoGenomics’ testing and informatics into everyday oncology workflows. Combined with Starrett’s experience at Flatiron Health, this reinforces the idea that NeoGenomics is trying to build a differentiated data and software layer around its core lab services, which could matter for both test adoption and the long term payoff from its heavy digital investments.

But while this all sounds encouraging, investors should also weigh the risk that ongoing losses and a high fixed cost base could still constrain NeoGenomics’ options...

NeoGenomics' narrative projects $982.4 million revenue and $59.9 million earnings by 2029.

Uncover how NeoGenomics' forecasts yield a $15.06 fair value, in line with its current price.

Exploring Other Perspectives

Some of the lowest analysts were assuming about US$965.8 million of revenue and only US$49.2 million of earnings by 2029, so compared with the AI and data upside implied by Starrett’s appointment and Epic integration, their view is far more cautious and is a useful reminder that your own expectations should be stress tested against very different outcomes.

Explore 2 other fair value estimates on NeoGenomics - why the stock might be worth just $15.06!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your NeoGenomics research is our analysis highlighting 1 important warning sign that could impact your investment decision.
• Our free NeoGenomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NeoGenomics' overall financial health at a glance.

Contemplating Other Strategies?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Capitalize on the AI infrastructure supercycle with our selection of the 53 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.